VERMOX
LOE ApproachingNDAORALTABLET, CHEWABLEPriority Review
Approved
Jun 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
VERMOX by Johnson & Johnson is mebendazole, a benzimidazole, is an anthelmintic [see ] . Approved for older with gastrointestinal infections caused by ascaris lumbricoides (roundworm), trichuris trichiura (whipworm), older with gastrointestinal infections caused by: ascaris lumbricoides (roundworm) and 1 more indications. First approved in 1974.
Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VERMOX is an oral chewable tablet small-molecule anthelmintic approved in 1974 by Johnson & Johnson. The drug treats parasitic worm infections through its mechanism of action against intestinal nematodes. It remains a standard-of-care option for helminthic diseases in both developed and resource-limited settings.
LOE Approaching
With LOE approaching and 30% competitive pressure, this mature franchise likely operates with a lean, efficiency-focused team managing decline and generic transition.
Mechanism of Action
Mebendazole, a benzimidazole, is an anthelmintic [see ] .
Worked on VERMOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.